Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Clinical Trials, Phase II as Topic × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡